На этой странице перечислены больницы направления «Радиационная онкология» (включая Stomach Cancer Treatment) в Хайдарабад, Индия, включая KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills.
Спросите нас о «Stomach Cancer Treatment» в Хайдарабад, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 4 аккредитованных больниц (Радиационная онкология) в Хайдарабад, Индия
Рекомендуем🇮🇳 KIMS Hospitals, Secunderabad
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 743 отзывов).
🇮🇳 Yashoda Hospitals, Secunderabad
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 518 отзывов).
🇮🇳 Apollo Hospital DRDO
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Apollo Hospitals, Jubilee Hills
Больница занимает 4-е место в этом списке по указанному рейтингу (4.1/5, 44 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Радиационная онкология» указано среди её специализаций и она находится в Хайдарабад, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «stomach cancer treatment» в Хайдарабад, Индия?
Выбор подходящей больницы для «stomach cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Радиационная онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Stomach Cancer Treatment»
Stomach cancer (gastric adenocarcinoma) is treated through a multidisciplinary protocol combining surgery, perioperative chemotherapy, targeted therapy, and—where indicated—immunotherapy; experienced oncology centers in India and the UAE achieve 5-year overall survival rates of 30–60% depending on stage at diagnosis. International patients choose GAF Healthcare to access high-volume gastric oncology units staffed by surgeons trained at leading Western and Asian cancer institutes, at a fraction of the cost they would pay at home. GAF Healthcare coordinates every clinical and logistical detail—from staging workup through post-operative surveillance—across its partner network of NABH- and JCI-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi. Hospital Stay: 10–21 days (varies by extent of resection: distal gastrectomy vs. total gastrectomy, open vs. robotic) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (intercontinental flight is generally permitted once the surgical wound is fully closed, nutritional intake is adequate via oral or enteral route, and the treating surgeon issues medical clearance) • Success Rate: Stage I: 70–90% 5-year survival; Stage II: 45–65%; Stage III: 20–40%; Stage IV (palliative intent): median survival 12–18 months with modern systemic therapy
Clinical Overview
Gastric cancer arises predominantly from the glandular epithelium of the stomach lining (adenocarcinoma in ~95% of cases) and is further classified by anatomic location (cardia/gastro-esophageal junction vs. body vs. antrum/pylorus), Lauren histological subtype (intestinal, diffuse, or mixed), and molecular subtype per The Cancer Genome Atlas (TCGA) classification—Epstein-Barr virus-positive, microsatellite instable (MSI-H), chromosomally instable (CIN), and genomically stable (GS). Helicobacter pylori infection, atrophic gastritis, intestinal metaplasia, smoking, high-salt diets, and hereditary diffuse gastric cancer (CDH1 germline mutations) are the principal etiological drivers. Physiologically, tumor growth disrupts gastric acid secretion, impairs digestion, and commonly causes protein-calorie malnutrition; advanced disease may obstruct the gastric outlet or invade adjacent structures (pancreas, transverse colon, liver), producing ascites, peritoneal carcinomatosis, or hepatic metastases. Accurate staging is the cornerstone of treatment planning and is performed using a combination of upper GI endoscopy with biopsy, endoscopic ultrasound (EUS) for T- and N-staging, contrast-enhanced CT of the chest, abdomen, and pelvis, and PET-CT to detect occult distant metastases. Diagnostic laparoscopy with peritoneal cytology is recommended for all patients with cT3–T4 or node-positive disease before committing to curative resection, as up to 20–30% harbor peritoneal disease not visible on cross-sectional imaging. Molecular profiling—including HER2 amplification by IHC/FISH, microsatellite instability (MSI/MMR) testing, PD-L1 combined positive score (CPS), VEGFR-2 expression, and FGFR2b amplification—is mandatory to guide first-line systemic therapy selection. The current international standard of care for resectable gastric cancer is perioperative chemotherapy (FLOT regimen: docetaxel, oxaliplatin, leucovorin, 5-fluorouracil) combined with D2 lymphadenectomy gastrectomy, consistent with the FLOT4-AIO trial data demonstrating superiority over ECF/ECX. For HER2-positive metastatic disease, trastuzumab combined with platinum-fluoropyrimidine doublet chemotherapy remains first-line per the ToGA trial, with trastuzumab deruxtecan (T-DXd) approved in the second-line setting. MSI-H tumors derive exceptional benefit from immune checkpoint inhibitors (nivolumab, pembrolizumab), and the KEYNOTE-811 and CheckMate 649 trials have established immunotherapy combinations as standard first-line options for advanced disease. Multidisciplinary tumor board review—comprising gastric surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, nutritionists, and palliative care specialists—is conducted at all GAF Healthcare partner centers before initiating treatment.
Who is a Candidate?
• ELIGIBLE FOR CURATIVE SURGICAL RESECTION: • Clinical stage IA–IIIC (cT1–T4a, N0–N3, M0) confirmed by EUS, CT, PET-CT, and diagnostic laparoscopy • Adequate cardiopulmonary reserve: ECOG performance status 0–2; left ventricular ejection fraction ≥50% (required before anthracycline-based chemotherapy); FEV1 ≥1.0 L for total gastrectomy candidates • Nutritional optimization achievable: albumin >3.0 g/dL or correctable with pre-operative enteral nutrition; BMI considerations reviewed by bariatric-oncology team • Absence of peritoneal carcinomatosis on diagnostic laparoscopy with negative peritoneal cytology • No unresectable liver metastases (isolated resectable hepatic metastases may be considered within a clinical trial or multidisciplinary consensus) • ELIGIBLE FOR PALLIATIVE / SYSTEMIC THERAPY: • Stage IV disease (distant metastases, positive peritoneal cytology, unresectable T4b tumors) • Molecular profiling completed: HER2 IHC/FISH, MSI/MMR, PD-L1 CPS, FGFR2b • ECOG performance status 0–2 for doublet/triplet chemotherapy; PS 3 for best supportive care • REQUIRED PRE-TREATMENT DIAGNOSTICS: • Upper GI endoscopy with multiple biopsies (minimum 6–8 biopsies per ESMO guideline) • Endoscopic ultrasound (EUS) for T and N staging • Contrast-enhanced CT chest/abdomen/pelvis • PET-CT (18F-FDG) to exclude occult distant metastases • Diagnostic laparoscopy + peritoneal lavage cytology (cT3+ or node-positive) • Complete molecular panel: HER2, MSI-PCR or IHC (MLH1/MSH2/MSH6/PMS2), PD-L1 CPS by 22C3 assay, FGFR2b IHC/NGS • Comprehensive metabolic panel, CBC, LFTs, renal function, CEA, CA 19-9, CA 72-4 • Echocardiography if anthracycline use planned; pulmonary function tests if total gastrectomy anticipated • Nutritional assessment: albumin, prealbumin, transferrin; dietitian evaluation • RELATIVE CONTRAINDICATIONS / HIGH-RISK CONSIDERATIONS: • Diffuse peritoneal carcinomatosis (curative resection not indicated; hyperthermic intraperitoneal chemotherapy/HIPEC only within select trial protocols) • Severe cardiac comorbidity (NYHA Class III–IV heart failure, unstable angina, recent MI within 6 months) • Uncontrolled coagulopathy or active hemorrhagic diathesis • CDH1 germline mutation carriers with hereditary diffuse gastric cancer (HDGC) require prophylactic total gastrectomy discussion, which is a separate clinical pathway • Prior extensive upper abdominal surgery (relative; requires individualized surgical planning)
Treatment Options & Approaches
SURGICAL APPROACHES: 1. Distal (Subtotal) Gastrectomy with D2 Lymphadenectomy: Indicated for tumors of the antrum and pylorus (lower two-thirds of the stomach). At least 4–5 cm proximal margin from the tumor is required. Reconstruction is performed via Billroth II (gastrojejunostomy) or Roux-en-Y configuration to prevent bile reflux. D2 dissection removes lymph node stations 1–12 as defined by the Japanese Gastric Cancer Association (JGCA), and retrieval of a minimum of 16 lymph nodes is required for accurate N-staging. D2 lymphadenectomy is the global standard and is associated with superior disease-specific survival compared to D1 in high-volume centers. 2. Total Gastrectomy with D2 Lymphadenectomy: Required for proximal tumors (cardia, fundus, body), Siewert Type II–III gastroesophageal junction (GEJ) tumors, and cases where negative proximal margins cannot be achieved with subtotal resection. Esophagojejunostomy reconstruction (Roux-en-Y) restores GI continuity. A jejunal pouch (Hunt-Lawrence pouch) may be fashioned to improve post-gastrectomy nutritional outcomes. A feeding jejunostomy is routinely placed intraoperatively to support enteral nutrition during the perioperative period. 3. Minimally Invasive Gastrectomy (Laparoscopic and Robotic-Assisted): Laparoscopic distal gastrectomy for early gastric cancer (EGC, cT1–T2) is a well-validated approach with level I evidence (KLASS-01, JLSSG0901 trials), offering equivalent oncologic outcomes to open surgery with reduced blood loss, shorter hospital stay (6–9 days vs. 10–14 days), lower wound complication rates, and faster return to adjuvant chemotherapy. Robotic-assisted gastrectomy (da Vinci Xi system) offers enhanced 3D visualization, articulated wristed instruments enabling precise intracorporeal anastomosis, and a stable operating platform particularly advantageous for D2 dissection around the splenic hilum and hepatoduodenal ligament. GAF Healthcare partner centers in India (Mumbai, Chennai, Hyderabad) and the UAE (Dubai, Abu Dhabi) operate FDA-approved da Vinci robotic platforms. Robotic total gastrectomy for proximal and locally advanced tumors is increasingly performed at high-volume centers with outcomes equivalent to open surgery. 4. Endoscopic Resection (Endoscopic Submucosal Dissection / ESD): Reserved for early gastric cancer meeting expanded Gotoda criteria: differentiated histology, intramucosa (T1a), no ulceration, ≤2 cm; or differentiated T1a ≤3 cm with ulceration; or differentiated T1b sm1 ≤3 cm. ESD achieves en-bloc curative resection in expert hands without the morbidity of surgical resection. Performed under endoscopic guidance using electrosurgical knives (IT knife-2, Flush knife BT). Available at select partner centers in India and the UAE. SYSTEMIC THERAPY PROTOCOLS: 5. Perioperative Chemotherapy (FLOT Regimen — Standard of Care for Resectable Disease): Fluorouracil 2600 mg/m² continuous infusion 24h + leucovorin 200 mg/m² + oxaliplatin 85 mg/m² + docetaxel 50 mg/m², administered every 2 weeks. Four cycles pre-operatively and four cycles post-operatively (FLOT4-AIO: median OS 50 months vs. 35 months for ECF/ECX; pCR rate 16%). Granulocyte colony-stimulating factor (G-CSF) prophylaxis and antiemetic protocol (5-HT3 antagonist + dexamethasone + NK1 antagonist) are mandatory. 6. Adjuvant Therapy (Post-surgical, Asia-Pacific context): Capecitabine + Oxaliplatin (CAPOX) for 8 cycles post-D2 gastrectomy (CLASSIC trial: 3-year DFS 74% vs. 59%; HRR 0.56). S-1 monotherapy (tegafur/gimeracil/oteracil) is an alternative adjuvant option widely used in East/Southeast Asian patients per ACTS-GC data. 7. First-Line Metastatic Therapy: • HER2-positive (IHC 3+ or IHC 2+/FISH amplified): Trastuzumab + CAPOX or mFOLFOX6 (ToGA trial: median OS 13.8 months). Trastuzumab deruxtecan (T-DXd, DESTINY-Gastric01/02) achieves 40–42% ORR and 12–17 months OS in HER2+ second-line. • MSI-H/dMMR tumors: Pembrolizumab + chemotherapy (KEYNOTE-590/811) or Nivolumab + chemotherapy (CheckMate 649: mOS 14.4 months); pembrolizumab monotherapy approved for MSI-H solid tumors regardless of site. • HER2-negative, PD-L1 CPS ≥5: Nivolumab + FOLFOX or CAPOX (CheckMate 649). • FGFR2b-positive (IHC ≥2+ in ≥10% cells or FGFR2 amplification): Bemarituzumab + mFOLFOX6 (FIGHT trial) — available in clinical trial settings at partner centers. • Standard chemotherapy backbone: mFOLFOX6, CAPOX, FOLFIRI ± ramucirumab (VEGFR-2 inhibitor, second-line, RAINBOW trial: mOS 9.6 months). 8. Radiation Therapy: Chemoradiation (45 Gy in 25 fractions with concurrent 5-FU/leucovorin or capecitabine) is used in the adjuvant setting for R1 resection (positive margins) or when D2 lymphadenectomy was not performed (INT-0116 protocol). Intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) minimize dose to kidneys, spinal cord, and liver at partner centers equipped with Elekta Versa HD or Varian TrueBeam linear accelerators. 9. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): For selected patients with limited peritoneal carcinomatosis (Peritoneal Cancer Index ≤6), cytoreductive surgery (CRS) + HIPEC (cisplatin 75 mg/m² + mitomycin-C 15 mg/m² at 41–42°C for 60–90 minutes) offers potential for long-term disease control at highly specialized centers. This approach remains investigational for gastric cancer and is offered only within multidisciplinary consensus at select partner institutions.
Восстановление
PHASE 1 — PRE-ARRIVAL PREPARATION (Weeks 1–3 before travel): • GAF Healthcare coordinator collects existing pathology reports, imaging (CT/PET-CT DICOM files), endoscopy reports, and blood work and submits to the designated oncology team for remote multidisciplinary tumor board review. • A written second-opinion report and individualized treatment plan (surgical vs. chemotherapy-first vs. palliative) is issued within 5–7 business days. • Visa assistance initiated: e-Medical visa (India) processed in 3–5 business days; UAE entry visa or visa-on-arrival arranged as applicable. • Nutritional prehabilitation initiated: patients with albumin <3.0 g/dL begin enteral or high-protein oral supplementation; smoking cessation mandatory. • FLOT pre-operative chemotherapy (if applicable) may begin at the patient's home country after protocol review, or at the partner center after arrival. PHASE 2 — ARRIVAL & STAGING CONFIRMATION (Days 1–4 in country): • Airport pickup by GAF Healthcare-assigned driver; direct transfer to hospital or partner accommodation. • Day 1–2: Repeat or confirmatory staging workup: upper GI endoscopy, EUS, CT, PET-CT (if not recently performed or if >8 weeks old). • Day 2–3: Diagnostic laparoscopy under general anesthesia (1-day procedure) to confirm absence of peritoneal disease if indicated; peritoneal wash cytology sent. • Day 3–4: Multidisciplinary tumor board meeting at the treating center; final treatment plan confirmed. Anesthesia pre-assessment, cardiology clearance, nutritional assessment completed. Jejunostomy feeding tube placement discussed. • Patient and family meet the primary surgeon, medical oncologist, and oncology nurse navigator. PHASE 3 — PRE-OPERATIVE CHEMOTHERAPY (If FLOT perioperative protocol, Weeks 1–8 pre-surgery): • 4 cycles of FLOT administered at the partner center's oncology day unit over 8 weeks (each cycle q2w). • Imaging restaging (CT/PET-CT) after Cycle 4 to assess response. • Nutritional support, anti-emetic management, and G-CSF administration supervised throughout. • Patients may return home between chemotherapy cycles if the treating team approves; re-admission 1 week before surgery. PHASE 4 — SURGERY (Day of operation + Hospital Days 1–14): • Surgical technique selected based on tumor location and stage: robotic-assisted or laparoscopic distal/total gastrectomy with D2 lymphadenectomy, or open gastrectomy for locally advanced tumors requiring multi-visceral resection. • Operative duration: 3–6 hours (robotic/laparoscopic); 4–7 hours (open multi-visceral). • Intraoperative frozen section of proximal and distal margins confirmed. • Feeding jejunostomy placed; nasogastric tube inserted. • ICU observation: 24–48 hours post-operatively for monitoring of anastomotic integrity, hemodynamics, and respiratory function. • Hospital Day 2–4: Early mobilization with physiotherapist; jejunostomy feeds commenced at 20 mL/hour and titrated. • Hospital Day 4–5: Water swallow test / contrast swallow study to confirm anastomotic integrity before initiating oral fluids. • Hospital Day 5–7: Oral intake progressed from clear liquids → soft puree diet; drain outputs assessed. • Hospital Day 7–10: Surgical drains removed if amylase-poor and serous; discharge criteria assessed (tolerating soft diet, afebrile, mobile). • Minimally invasive cases: discharge typically Day 7–9. Open multi-visceral resection: discharge Day 10–14. • Final histopathology and lymph node count reviewed; pTNM staging confirmed; R0/R1 status documented. PHASE 5 — POST-OPERATIVE RECOVERY & ADJUVANT THERAPY (Weeks 2–8 in country): • Week 2–3: Weekly outpatient follow-up with surgeon and oncology dietitian. Jejunostomy feeds weaned as oral caloric targets met (>60% of requirements orally). Wound check, staple/suture removal. • Week 3–4: Oncology review; initiation of adjuvant FLOT (cycles 5–8) or CAPOX if perioperative protocol used, approximately 4–6 weeks post-surgery. • Vitamin B12, iron, calcium, vitamin D supplementation initiated (mandatory for all gastrectomy patients to prevent post-gastrectomy metabolic complications). • Dumping syndrome education; dietary modification counseling by specialized oncology dietitian. • Week 4–8: Completion of initial adjuvant chemotherapy cycles if remaining treatment is conducted at the partner center. Patients who wish to continue adjuvant chemotherapy at home receive a detailed written protocol and coordination letters. • FIT-TO-FLY MILESTONE: International flight permitted when (a) surgical wound fully healed with no active drainage, (b) tolerating ≥1000 kcal/day orally or via jejunostomy, (c) no anastomotic leak or intra-abdominal collection on imaging, (d) DVT prophylaxis plan in place for flight (low-molecular-weight heparin), and (e) written surgical clearance issued. This typically occurs 4–6 weeks post-surgery for minimally invasive cases and 6–8 weeks for complex open resections. PHASE 6 — LONG-TERM SURVEILLANCE (Home country, with GAF telemedicine support): • CT chest/abdomen/pelvis every 6 months for 3 years, then annually. • Upper GI endoscopy at 1 year post-surgery for partial gastrectomy patients. • CEA, CA 19-9 monitoring every 3–6 months. • Annual vitamin B12, iron studies, bone density scan (DEXA) after total gastrectomy. • GAF Healthcare telemedicine follow-up connects the patient's home oncologist with the treating center.
Возможные риски
Stomach cancer surgery and multimodal treatment carry significant risks that patients must discuss in detail with their multidisciplinary team before proceeding. Surgical risks include anastomotic leak (incidence 2–8% after total gastrectomy; managed with radiologically guided drainage or reoperation), duodenal stump blow-out (rare, ~1–2%, life-threatening), intra-abdominal abscess, delayed gastric emptying, and bile reflux gastritis. The Clavien-Dindo classification is used at all GAF partner centers to grade and benchmark post-operative complications; 30-day mortality at high-volume JCI-accredited centers is <2% for elective gastrectomy. Dumping syndrome (early and late) affects 10–20% of patients and requires strict dietary management. Nutritional deficiencies—particularly vitamin B12, iron, calcium, and fat-soluble vitamins—are universal after total gastrectomy and require lifelong supplementation. Chemotherapy-specific risks include peripheral neuropathy (oxaliplatin, cumulative and dose-dependent), febrile neutropenia (FLOT: ~25% incidence; managed with G-CSF), hand-foot syndrome (capecitabine), and cardiotoxicity (anthracyclines used in ECX/ECF regimens, less common with FLOT). Trastuzumab carries a 4–8% risk of asymptomatic left ventricular dysfunction and requires ECHO monitoring every 3 cycles. Immune checkpoint inhibitors (nivolumab, pembrolizumab) may cause immune-related adverse events (irAEs) including immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and severe skin reactions (grade 3–4 irAE incidence ~14%); high-dose corticosteroid management protocols are in place at all partner centers. For international patients specifically, the risks of long-haul air travel following major abdominal surgery include deep vein thrombosis (DVT) and pulmonary embolism; all patients traveling internationally post-gastrectomy receive individualized DVT prophylaxis plans including low-molecular-weight heparin, compression stockings, and in-flight mobility guidance. GAF Healthcare's clinical coordinators monitor all patients until fit-to-fly criteria are met and coordinate emergency medical support in the rare event of post-discharge complications.
Почему GAF Healthcare
GAF Healthcare provides a dedicated end-to-end non-medical support infrastructure designed specifically for international oncology patients. VISA & ENTRY ASSISTANCE: For India: GAF Healthcare facilitates the e-Medical Visa application through the Indian government's e-Visa portal. The e-Medical Visa allows a stay of up to 60 days (triple-entry), is typically approved within 3–5 business days, and also covers one accompanying attendant (e-Medical Attendant Visa). Required documents include a letter from the treating Indian hospital (provided by GAF), passport copy, and recent photographs. For the UAE (Dubai and Abu Dhabi): Citizens of over 100 countries receive a free-of-charge visa on arrival for 30–90 days. GCC nationals, EU/UK/US/Canadian passport holders, and many Asian nationals do not require pre-arranged visas. For nationalities requiring advance visas, GAF Healthcare's UAE coordination team facilitates Medical Entry Permits through the DHA (Dubai Health Authority) or DOH (Abu Dhabi Department of Health), typically approved within 5–7 business days. AIRPORT TRANSFERS & GROUND LOGISTICS: A GAF Healthcare-assigned vehicle with a trained medical escort (for patients requiring oxygen or IV medication during transit) meets every patient at the arrival terminal. Wheelchair assistance is pre-arranged for patients with reduced mobility. All transfers between airport, hospital, and accommodation are managed by the GAF ground team. MEDICAL TRANSLATION & LANGUAGE SUPPORT: Dedicated medical interpreters are available in Arabic, Russian, Kazakh, Uzbek, Swahili, Amharic, and French at partner centers in both India and the UAE. Clinical documents, consent forms, discharge summaries, and chemotherapy protocols are translated into the patient's preferred language. A bilingual GAF patient coordinator is assigned as a single point of contact throughout the treatment journey and is reachable 24/7. ACCOMMODATION FOR PATIENTS & ATTENDANTS: GAF Healthcare partners with service apartments and hotels adjacent to all partner hospitals at pre-negotiated rates ranging from USD 30–80/night (India) and USD 80–200/night (UAE). Accommodations are equipped with kitchenettes (essential for post-gastrectomy dietary management), wheelchair accessibility, and proximity to hospital outpatient facilities for daily chemotherapy or wound review visits. Long-stay discounts of 15–25% are available for gastrectomy patients who require 4–8 weeks in-country. Meals compliant with the oncology dietitian's post-gastrectomy prescription (small, frequent, low-sugar, low-fat, soft-texture diet) are arrangeable through hospital dietary services or partner catering providers. TELEMEDICINE & POST-DISCHARGE COORDINATION: Upon returning home, each patient receives a detailed discharge summary in English (and translated into their language), a surveillance schedule, and a GAF telemedicine link enabling video consultations with the treating surgical oncologist and medical oncologist at regular intervals. GAF coordinates sharing of follow-up imaging and blood results between the home oncologist and the treating center to ensure continuity of care.
Частые вопросы о процедуре «Stomach Cancer Treatment»
What is the cost of Stomach Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after stomach cancer surgery?
What is the success rate of stomach cancer treatment?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «stomach cancer treatment» в Хайдарабад, Индия
Найдите лучшие больницы для «stomach cancer treatment» в Хайдарабад, Индия
На этой странице представлено 4 больниц в Хайдарабад, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Stomach Cancer Treatment» в Хайдарабад, Индия
Сколько больниц направления «Радиационная онкология» представлено в Хайдарабад, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Хайдарабад, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Stomach Cancer Treatment» в Хайдарабад, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.